Over the course of the projection period, it is anticipated that increased research and development to create genital wart treatments will boost market growth. For instance, the South African universities of Pretoria and Stellenbosch are working together to undertake clinical trials to examine the efficacy of the human papilloma virus (HPV) vaccination against the development of genital warts. The investigation began in 2018 and is anticipated to be finished in 2023. The investigation is currently in the Phase III clinical trial stage.
The global Genital Warts Treatment Market is estimated to be valued at US$ 1,628.9 million in 2021 and is expected to exhibit a CAGR of 4.7% over the forecast period (2021-2028).
Key Leaders in the Genital Warts Treatment Industry:
1. Sanofi S.A
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. Sanofi was founded in 1973 and is headquartered in Paris, France. It also has a collaboration and license option agreement with Prellis Biologics, Inc. in 2021 December, Sanofi to acquired Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics.
2. Perrigo Company plc
Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through two segments, Consumer Self-Care Americas and Consumer Self-Care International. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
3. AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide since 2012. It is headquartered in North Chicago and operational in more than 70 countries. AbbVie and HotSpot Therapeutics, Inc., in December, 2022 announced an exclusive worldwide collaboration and option to license agreement for HotSpot's discovery-stage IRF5 program for the treatment of autoimmune diseases.
4. 3M Company
3M is an America-based company that was established in the year 1929. It is a major player in the Wound Care industry. The company operates through five segments globally. In order to retain its share in the market, the company focuses on launching new and advanced products. Moreover, 3M Health Care's Medical Solutions Division announced, in October 2022, that it’s 3M V.A.C. Therapy negative pressure wound therapy (NPWT) surpassed a clinical evidence milestone of 2,000 published, peer-reviewed medical journal studies. V.A.C. This is the first and only NPWT solution to garner this number of published studies about its therapy.
5. Lee's Pharmaceutical Holdings Ltd
Lee Pharma Limited has been established in 1997 in India which is research driven company with key focus on development, synthesis and commercialization of new products and cost effective processes. The company has headquarters situated in Hyderabad, India.
6. Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products. The company was incorporated in 1977 and is based in Mumbai, India. In January, 2023 Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce it has launched Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) SingleDose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multi-Dose Vials, the generic version of Bumex®1 Injection, 0.25 mg/mL, of Validus Pharmaceuticals LLC.
7. Bausch Health Companies Inc
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It was founded in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada. On Aug. 10, 2022 Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals, announced its support of the publication of a new specific ICD-10 code from the Centers for Medicare & Medicaid Services (CMS) for hepatic encephalopathy (HE) based on the growing incidence of chronic liver disease in the United States.
8. Novartis AG.
The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. Novartis in December, 2022 announced the European Commission (EC) approved Pluvicto® (INN: lutetium (177Lu) vipivotide tetraxetan), a targeted radioligand therapy
*Definition- Genital warts are a type of sexually transmitted infection that are typically brought on by the HPV virus (HPV). Additionally, some types of cancer have been linked to HPV.
